BioCentury | Jul 20, 2018
Clinical News

Spyryx's SPX-101 improves lung function in Phase II CF trial

...family A member 1 (BPIFA1; SPLUNC1; PLUNC; LUNX) that prevents epithelial sodium channel (ENaC) activation. Spyryx Biosciences Inc....
...safety and clinical laboratory tests Status: Phase II data Milestone: Additional Phase II data (1H19) Jennie Walters SPX-101 Spyryx Biosciences Inc. BPI...
BioCentury | Dec 1, 2017
Clinical News

Spyryx starts Phase II for CF

...A member 1 (BPIFA1; SPLUNC1; PLUNC; LUNX)-derived peptide that prevents epithelial sodium channel (ENaC) activation. Spyryx Biosciences Inc....
...in clinical laboratory tests from baseline at day 28 Status: Phase II started Milestone: NA Allison Johnson SPX-101 Spyryx Biosciences Inc. BPI...
BioCentury | May 5, 2017
Clinical News

Spyryx reports positive Ph I safety data for SPX-101

...In February, Spyryx Biosciences Inc. (Durham, N.C.) reported that single and multiple ascending doses of inhaled SPX-101 for...
...mid-year, Spyryx plans to start a Phase II trial of SPX-101 in patients with CF. Spyryx Biosciences Inc....
...CF) Endpoint: Safety and pharmacokinetics Status: Phase I data Milestone: Start Phase II (mid-2017) Alex Himes SPX-101 Pari GmbH Spyryx Biosciences Inc. BPI...
BioCentury | Nov 11, 2016
Clinical News

SPX-101: Preclinical data

...for CF. Spyryx Biosciences Inc. , Durham, N.C. Product: SPX-101 Business: Pulmonary Indication: Treat cystic fibrosis (CF) Julian Zhu Spyryx Biosciences Inc. BPI...
BioCentury | Aug 24, 2016
Company News

Management tracks

...the company. NeuroVive said the position is no longer needed following a reorganization. Respiratory company Spyryx Biosciences Inc....
BioCentury | Aug 3, 2015
Emerging Company Profile

Going SPLUNCing

...and Institutions Mentioned Cystic Fibrosis Foundation Therapeutics Inc., Bethesda, Md. Parion Sciences Inc., Durham, N.C. Spyryx Biosciences Inc....
...fibrosis airway epithelial cultures." American Journal of Physiology Lung Cellular and Molecular Physiology (2013) Sidebars Spyryx Biosciences Inc....
BioCentury | May 11, 2015
Financial News

Spyryx Biosciences completes venture financing

Spyryx Biosciences Inc. , Research Triangle Park, N.C. Business: Pulmonary Date completed: 2015-05-07 Type: Venture financing Raised: $18 million Investors: Canaan Partners; Hatteras Venture Partners; 5AM Ventures WIR Staff Pulmonary...
BioCentury | May 8, 2015
Financial News

Spyryx raises $18M in series A

...Respiratory newco Spyryx Biosciences Inc. (Research Triangle Park, N.C.) raised $18 million in a series A round from...
Items per page:
1 - 8 of 8
BioCentury | Jul 20, 2018
Clinical News

Spyryx's SPX-101 improves lung function in Phase II CF trial

...family A member 1 (BPIFA1; SPLUNC1; PLUNC; LUNX) that prevents epithelial sodium channel (ENaC) activation. Spyryx Biosciences Inc....
...safety and clinical laboratory tests Status: Phase II data Milestone: Additional Phase II data (1H19) Jennie Walters SPX-101 Spyryx Biosciences Inc. BPI...
BioCentury | Dec 1, 2017
Clinical News

Spyryx starts Phase II for CF

...A member 1 (BPIFA1; SPLUNC1; PLUNC; LUNX)-derived peptide that prevents epithelial sodium channel (ENaC) activation. Spyryx Biosciences Inc....
...in clinical laboratory tests from baseline at day 28 Status: Phase II started Milestone: NA Allison Johnson SPX-101 Spyryx Biosciences Inc. BPI...
BioCentury | May 5, 2017
Clinical News

Spyryx reports positive Ph I safety data for SPX-101

...In February, Spyryx Biosciences Inc. (Durham, N.C.) reported that single and multiple ascending doses of inhaled SPX-101 for...
...mid-year, Spyryx plans to start a Phase II trial of SPX-101 in patients with CF. Spyryx Biosciences Inc....
...CF) Endpoint: Safety and pharmacokinetics Status: Phase I data Milestone: Start Phase II (mid-2017) Alex Himes SPX-101 Pari GmbH Spyryx Biosciences Inc. BPI...
BioCentury | Nov 11, 2016
Clinical News

SPX-101: Preclinical data

...for CF. Spyryx Biosciences Inc. , Durham, N.C. Product: SPX-101 Business: Pulmonary Indication: Treat cystic fibrosis (CF) Julian Zhu Spyryx Biosciences Inc. BPI...
BioCentury | Aug 24, 2016
Company News

Management tracks

...the company. NeuroVive said the position is no longer needed following a reorganization. Respiratory company Spyryx Biosciences Inc....
BioCentury | Aug 3, 2015
Emerging Company Profile

Going SPLUNCing

...and Institutions Mentioned Cystic Fibrosis Foundation Therapeutics Inc., Bethesda, Md. Parion Sciences Inc., Durham, N.C. Spyryx Biosciences Inc....
...fibrosis airway epithelial cultures." American Journal of Physiology Lung Cellular and Molecular Physiology (2013) Sidebars Spyryx Biosciences Inc....
BioCentury | May 11, 2015
Financial News

Spyryx Biosciences completes venture financing

Spyryx Biosciences Inc. , Research Triangle Park, N.C. Business: Pulmonary Date completed: 2015-05-07 Type: Venture financing Raised: $18 million Investors: Canaan Partners; Hatteras Venture Partners; 5AM Ventures WIR Staff Pulmonary...
BioCentury | May 8, 2015
Financial News

Spyryx raises $18M in series A

...Respiratory newco Spyryx Biosciences Inc. (Research Triangle Park, N.C.) raised $18 million in a series A round from...
Items per page:
1 - 8 of 8